Undenatured type II collagen
Also called: native type II collagen, undenatured collagen type II, non-hydrolyzed type II collagen
Undenatured (native) type II collagen is a nutritional supplement derived from chicken sternum cartilage and taken at about 40 mg daily in trials. A 2025 review describes its proposed mechanism as an immune-mediated process known as oral tolerance.
- Category
- Amino acid and protein
- Forms
- Undenatured type II collagen from chicken sternum cartilage, in capsules (40 mg/day in most trials)
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2023 review with limited meta-analysis (Am J Transl Res) included 8 RCTs in knee osteoarthritis and pooled 6 RCTs (197 collagen, 190 control participants) of oral undenatured type II collagen alone versus placebo or control for WOMAC scores. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBones and joints5 topics
- BKnee osteoarthritis pain and function
- BKnee osteoarthritis (180-day trial versus placebo and glucosamine-chondroitin)
- BOsteoarthritis pain across supplements (meta-analysis)
- CKnee flexibility in healthy adults with activity-related joint discomfort
- CJoint function in healthy adults with activity-related discomfort (180 days)
CMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Knee osteoarthritis pain and function | B | A 2023 review of 8 RCTs (3–6 months) pooled 6 for WOMAC (MD -8.91) and 3 for VAS pain (MD -1.65), both favoring the collagen over placebo or control; Lequesne index did not differ. Authors call for larger trials. [1] |
| Knee osteoarthritis (180-day trial versus placebo and glucosamine-chondroitin) | B | In an RCT of 191 volunteers, 40 mg/day for 180 days reduced total WOMAC score versus placebo (p = 0.002) and versus glucosamine plus chondroitin (p = 0.04); safety outcomes did not differ among groups. [2] |
| Osteoarthritis pain across supplements (meta-analysis) | B | A 2018 meta-analysis of 69 placebo-controlled RCTs of 20 supplements found only green-lipped mussel extract and undenatured type II collagen had clinically important effects on pain at medium term. [6] |
| Exercise-related knee discomfort in healthy adults | C | In an RCT of 55 healthy adults, 40 mg/day for 120 days improved knee extension versus placebo (81.0° vs 74.0°; p = 0.011); time exercised before joint discomfort lengthened versus baseline. [3] |
| Knee flexibility in healthy adults with activity-related joint discomfort | C | In a multicenter RCT of 96 adults, 40 mg/day for 24 weeks increased knee flexion range of motion versus placebo (3.23° vs 0.21°; p = 0.025). [4] |
| Joint function in healthy adults with activity-related discomfort (180 days) | C | In an RCT of 74 healthy adults, KOOS joint-function scores improved in both the native type II collagen and placebo groups by day 180; improvements from baseline appeared earlier with the collagen. [5] |
Main constituents: Undenatured type II collagen protein, characterized in trials by an ELISA using a monoclonal antibody specific for epitopes expressed only by undenatured type II collagen [8]; Proposed to act through oral tolerance, an immune-mediated mechanism, per a 2025 review [7]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 40 mg/day for 180 days in a knee osteoarthritis RCT. [2]
- 40 mg/day for 120 days in healthy volunteers with exercise-related knee discomfort. [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In a 180-day RCT of 191 people with knee osteoarthritis, safety outcomes did not differ among the undenatured type II collagen, glucosamine-chondroitin and placebo groups. [2]
- In a 120-day RCT in healthy volunteers, no product-related adverse events were observed. [3]
- A 2023 review of 8 RCTs found overall complications similar to other supplements. [1]
Identity, quality and standardization
- Published trials characterized undenatured type II collagen content by an ELISA with an epitope-specific monoclonal antibody; a 2014 change to sample preparation altered the percent of undenatured collagen reported for the same commercial material. [8]
Regulatory status
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [9]
- US: FDA's published NDI notification list has 1 entry named "Type II Collagen" (NDI 103, submitted 2000-11-20) that does not state whether the material is undenatured; NDI 233 (2003-05-21) names a hydrolyzed (denatured) chicken sternal type II collagen, a different material. [10]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Undenatured type II collagen derived from chicken sternum cartilage Amino acids, amines and peptides (protein) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming type II collagen (earliest NDI 103, "Type II Collagen", submitted 2000-11-20; most recent NDI 233 submitted 2003-05-21, which names hydrolyzed (denatured) chicken sternal type II collagen, a different material). NDI 103 does not state whether its material is undenatured. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P5]
- Undenatured type II collagen content by ELISA with a monoclonal antibody specific for epitopes expressed only by undenatured type II collagen; report the sample-preparation method — Clinical trial materials were characterized this way, and a 2014 change in sample preparation altered the percent of undenatured collagen reported for the same material. [P6]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Lugo JP, et al. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J 2016;15:14 (PMID 26822714), 2016-01-29. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Cumulative Cross Index to IARC Monographs Volumes 1 to 142 (PDF, retrieved 2026-10-30), 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
- Lugo JP. Letter to the editor: undenatured type II collagen, update to analytical methods. J Int Soc Sports Nutr 2019;16(1):29 (PMID 31311550), 2019-07-16. pubmed.ncbi.nlm.nih.gov
Sources
- Kumar P, et al. Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis. Am J Transl Res 2023;15(9):5545-5555 (PMID 37854210), 2023-09-15. pubmed.ncbi.nlm.nih.gov
- Lugo JP, et al. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J 2016;15:14 (PMID 26822714), 2016-01-29. pubmed.ncbi.nlm.nih.gov
- Lugo JP, et al. Undenatured type II collagen for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr 2013;10(1):48 (PMID 24153020), 2013-10-24. pubmed.ncbi.nlm.nih.gov
- Schön C, et al. Undenatured type II collagen for knee joint flexibility: a multicenter, randomized, double-blind, placebo-controlled clinical study. J Integr Complement Med 2022;28(6):540-548 (PMID 35377244), 2022-06. pubmed.ncbi.nlm.nih.gov
- Möller I, et al. Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study. Nutr J 2026;25(1):46 (PMID 41787523), 2026-03-06. pubmed.ncbi.nlm.nih.gov
- Liu X, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med 2018;52(3):167-175 (PMID 29018060), 2018-02. pubmed.ncbi.nlm.nih.gov
- Gupta A, Maffulli N. Undenatured type II collagen for knee osteoarthritis. Ann Med 2025;57(1):2493306 (PMID 40253594), 2025-04-20. pubmed.ncbi.nlm.nih.gov
- Lugo JP. Letter to the editor: undenatured type II collagen, update to analytical methods. J Int Soc Sports Nutr 2019;16(1):29 (PMID 31311550), 2019-07-16. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.